CRNX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Crinetics Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 83.73 USD
-0.2% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 85.9% above the Trend Line and sits at 99.5% of its 52-week range. The latest completed week returned -0.2%, after a 128.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bullish with 47/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high; earnings are due in 4d.

Setup score 54 out of 100
Latest Close 83.73 USD 24 Jul 2026
1W Return -0.2% latest completed week
4W Return 128.1% short-term follow-through
12W Return 114.6% quarterly tape
Trend Breadth 48.1% 25 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • The trend backdrop is active with a 2-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 4 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.2% Latest completed week; four-week move 128.1%. Indicator stack 33/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 47/100 conviction; expected move 1.3%. News sentiment 54/100 67 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 85.9% above the Trend Line and sits at 99.5% of its 52-week range. The latest completed week returned -0.2%, after a 128.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2312-week average 0.08

12-week confirmation

Trend active2/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership3/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.23Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 128.1% over four weeks, 114.6% over 12 weeks, and 170.2% over one year. The current trend has remained active for 2 consecutive weeks.

Performance by holding period

1W-0.2%
4W128.1%
12W114.6%
26W57.4%
52W170.2%
Active trend streak2 weeks
Active weeks in one year25
Trend breadth48.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.39Latest activity-pressure read.
Pressure change1206.0%Four-week change in activity pressure.
Leadership80.17Latest relative-leadership reading.
RS change520.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength66/100Blend of value, momentum, and quality. Underlying universe rank 35; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
490.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-4.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.9%
Gross profit retained from each unit of revenue.
Operating margin
-2746.2%
Operating profit retained from revenue.
Free-cash-flow margin
-2262.6%
Free cash flow generated from revenue.
Return on invested capital
-30.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-4.3%
Net share repurchases relative to market value.
Shareholder yield
-4.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

CRNX shows bullish options pressure with a 47/100 conviction score, put-call volume ratio of 0.66, expected move of 1.3%, and Sharemaestro trend signal active.

Conviction47/100
Expected move1.3%
Put/call volume0.66
Pressure26
Speculation40
Volatility14
Trend agreement100
Open options detail
Insider activity15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 67 relevant articles.

18 positive · 43 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move1.3%Nearest-chain priced movement where available.
52-week drawdown-0.3%Distance below the 52-week high.
13-week volatility26.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+97.9%Week of 10 Jul.
Worst week-9.3%Week of 6 Feb.
Latest week-0.2%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks0
Modest losses5
Sharp losses9
Recent vol26.3%13-week weekly-return volatility.
Base vol15.6%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew10.5% / -4.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape49/100

Trend, activity pressure, participation, and risk combine to a 49/100 tape read.

 Indicator analysis20/100

Latest 12-week confirmation: trend 2/12, activity pressure 4/12, relative leadership 3/12.

Activity pressure 0.23; 4 reversal markers Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 82; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options74/100

CRNX shows bullish options pressure with a 47/100 conviction score, put-call volume ratio of 0.66, expected move of 1.3%, and Sharemaestro trend signal active.

Bullish · Call-side pressure · Expected move 1.3% Sentiment54/100

Weighted news tone is neutral across 67 relevant articles.

Crinetics Pharmaceuticals Inc (CRNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders15 / 5

15 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202683.73 USD-0.2%45.05 USD40.64 USD1.3980.1717.9MOn
17 Jul 202683.86 USD0.3%43.86 USD40.23 USD1.1781.0223.7MOn
10 Jul 202683.58 USD97.9%42.66 USD39.81 USD0.7576.22120.2MOff
3 Jul 202642.23 USD15.1%41.56 USD39.40 USD0.26-7.795.0MOff
26 Jun 202636.70 USD2.3%41.71 USD39.25 USD-0.13-19.0510.2MOff
19 Jun 202635.87 USD4.1%42.00 USD39.13 USD-0.44-24.504.4MOff
12 Jun 202634.47 USD4.7%42.24 USD39.02 USD-0.55-25.715.3MOff
5 Jun 202632.92 USD-7.4%42.51 USD38.93 USD-0.60-27.694.6MOff
29 May 202635.55 USD-3.4%42.75 USD38.86 USD-0.53-25.784.5MOff
22 May 202636.80 USD0.1%43.01 USD38.77 USD-0.50-21.203.9MOff
15 May 202636.77 USD-1.9%43.15 USD38.68 USD-0.62-20.486.8MOff
8 May 202637.48 USD-3.9%43.31 USD38.59 USD-0.76-19.4010.2MOff
1 May 202639.02 USD1.8%43.56 USD38.49 USD-0.84-11.757.1MOff
24 Apr 202638.33 USD-6.5%43.62 USD38.38 USD-1.00-12.264.6MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.